StockNews.com Initiates Coverage on Aspira Women’s Health (NASDAQ:AWH)

Stock analysts at StockNews.com began coverage on shares of Aspira Women’s Health (NASDAQ:AWH) in a research report issued to clients and investors on Wednesday. The firm set a “hold” rating on the stock.

Aspira Women’s Health Trading Down 0.3 %

NASDAQ AWH opened at $0.77 on Wednesday. The company has a market capitalization of $12.83 million, a price-to-earnings ratio of -0.64 and a beta of 1.39. The stock’s 50 day moving average is $0.82 and its two-hundred day moving average is $1.04. Aspira Women’s Health has a 1-year low of $0.67 and a 1-year high of $5.65.

Hedge Funds Weigh In On Aspira Women’s Health

A hedge fund recently bought a new stake in Aspira Women’s Health stock. Pine Valley Investments Ltd Liability Co acquired a new stake in shares of Aspira Women’s Health Inc. (NASDAQ:AWH) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 31,200 shares of the company’s stock, valued at approximately $25,000. Pine Valley Investments Ltd Liability Co owned about 0.19% of Aspira Women’s Health at the end of the most recent reporting period. 12.19% of the stock is owned by hedge funds and other institutional investors.

About Aspira Women’s Health

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.